In vitro method to generate dendritic Langerhans type cells
View Patent ↗Described is an in vitro method for developing dendritic Langerhans type cells, for use in immunotherapy against cancer or infectious diseases and enhancement of graft survival in mammals. The method includes the steps of: culturing cells selected from peripheral blood monocytes and bone marrow cells in a medium containing platelets obtained from the same species or phylogenetically close species; and incubating the culture at 30 to 40° C. for a period sufficient to enable formation of mature dendritic Langerhans type cells.
1. An in vitro method for generating mammalian dendritic Langerhans type cells, said method comprising:
a. culturing cells selected from the group consisting of peripheral blood monocytes and bone marrow cells from a mammalian species in a medium containing platelets obtained from the same species;
b. incubating the culture at 30° C. to 40° C. for a period sufficient to enable in vitro generation of dendritic Langerhans type cells,
c. performing a morphological analysis of the in vitro generated dendritic Langerhans type cells; and
d. performing flow cytometric analysis of the in vitro generated dendritic Langerhans type cells.
2. The method of claim 1 wherein the medium omits an exogenous cytokine.
3. The method of claim 1 wherein the medium comprises RPMI-1640.
4. The method of claim 1 wherein the cells are cultured for a period of 2 to 8 days.
5. The method of claim 1 wherein the medium further comprises at least 2 percent fetal calf serum.
6. The method of claim 1 wherein the mammalian species is human.
7. An in vitro method for generating human dendritic Langerhans type cells, said method comprising:
a. culturing human peripheral blood monocytes in a medium containing human platelets;
b. incubating the culture at 30° C. to 40° C. for a period sufficient to enable in vitro generation of human dendritic Langerhans type cells,
c. performing a morphological analysis of the in vitro generated dendritic Langerhans type cells; and
d. performing flow cytometric analysis of the in vitro generated dendritic Langerhans type cells.
8. The method of claim 7 wherein the medium omits an exogenous cytokine.
9. The method of claim 7 wherein the medium comprises RPMI-1640.
10. The method of claim 7 wherein the cells are cultured for a period of 2 to 8 days.
11. The method of claim 7 wherein the medium further comprises at least 2 percent fetal calf serum.
12. The method of claim 6 , wherein the flow cytometric analysis comprises immunophenotyping the in vitro generated dendritic Langerhans type cells by using a monoclonal antibody specific for a human cell surface marker, wherein the antibody is selected from anti-CD3, anti-HLADR, anti-CD19, anti-CD40, anti-CD1a, anti-CD1b, anti-CD80, anti-CD83and anti-CD86.
13. The method of claim 7 , wherein the flow cytometric analysis comprises using a monoclonal antibody specific for a human cell surface marker, wherein the antibody is selected from anti-CD3, anti-HLADR, anti-CD19, anti-CD40, anti-CD1a, anti-CD1b, anti-CD80, anti-CD83and anti-CD86.